FDA Grants Soricimed Orphan Status

Soricimed Biopharma Inc., the Moncton-based biotech company developing peptide-based cancer treatments, has announced the U.S. Food and Drug Administration has granted orphan drug designation to its flagship compound for the treatment of pancreatic cancer.
The FDA granted a similar designation earlier this year to the compound SOR-C13 for the treatment of ovarian cancer.
“Receiving orphan drug